In Brief: ArQule/Signal
ArQule/Signal: Companies expand alliance for discovery and optimization of novel therapeutic compounds that modulate gene expression. New agreement will provide for increased number of compounds to be evaluated in current and future Signal screening assays. Signal will generate drug leads using ArQule's Mapping Array compound sets; after leads are identified, the companies may apply ArQule's Directed Array technologies for optimization into clinical candidate compounds. Companies will share either ownership rights in compounds discovered or will receive milestones and royalties...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth